Benzinga | Apr 21, 2021 07:04AM EDT

TG Therapeutics Announces Launch Of ULTRA-V Phase 3 Trial Evaluating Triple Combination Of UKONIQ, Ublituximab, And Venetoclax

TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the initiation of patient enrollment into the ULTRA-V Phase 3 randomized trial, evaluating the time-limited triple combination of UKONIQ(tm) (umbralisib), the Company's once-daily, inhibitor of PI3K-delta and CK1-epsilon, ublituximab, the Company's investigational glycoengineered anti-CD20 monoclonal antibody, and venetoclax, compared to the continuous doublet combination of UKONIQ plus ublituximab (U2) in patients with both frontline and relapsed or refractory chronic lymphocytic leukemia (CLL). The primary endpoint for the ULTRA-V Phase 3 trial is Progression-free Survival (PFS), and the trial is designed support the full approval of the triple combination of U2 plus venetoclax.